8-K: Vireo Growth Inc. Reports Q1 2025 Financial Results, Revenue Up Slightly Amidst Pending Mergers

Vireo Growth Inc. announced its Q1 2025 financial results, showing a slight revenue increase and progress on pending merger transactions.

Summary

• Vireo Growth Inc. reported a 1.9% year-over-year increase in revenue for Q1 2025, reaching $24.5 million.
• Gross profit increased slightly to $12.4 million, with a gross profit margin of 50.6%.
• Operating income decreased significantly to $2.0 million, resulting in an operating income margin of 8.1%.
• Adjusted EBITDA increased by 8.5% to $6.6 million, with an adjusted EBITDA margin of 26.8%.
• The company ended Q1 with $86.3 million in cash.
• Merger transactions are expected to begin closing in Q2 2025.
• As of March 31, 2025, the company had 472,078,412 shares outstanding on a treasury method basis, using a share price of $0.45.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue growth is modest and operating income declined, the company maintains a strong cash position and is progressing with strategic mergers. The management's comments are cautiously optimistic.

Positives

• Revenue increased by 1.9% year-over-year to $24.5 million.
• Adjusted EBITDA increased by 8.5% to $6.6 million.
• The company maintains a strong cash position with $86.3 million on hand.
• Merger transactions are progressing and expected to close in Q2 2025.
• Maryland and Minnesota markets showed positive performance.

Negatives

• Operating income decreased by 58.5% to $2.0 million.
• Operating income margin decreased significantly from 19.8% to 8.1%.
• Medical sales declined in New York.
• SG&A expenses increased by 6.0% to $7.5 million.

Risks

• The company's pending mergers are subject to closing conditions and regulatory approvals.
• Changes in cannabis laws and regulations could impact the company's operations.
• The company faces risks related to market conditions and competition.
• The company's ability to raise additional financing is uncertain.
• The company is involved in a lawsuit with Verano.

Future Outlook

The company expects to close its pending merger transactions during the second quarter of 2025 and anticipates this will strengthen its profitability profile. Management will provide additional updates on its combined platform once the merger transactions have closed.

Management Comments

• Chief Executive Officer John Mazarakis commented, 'First quarter results were in line with our expectations for Vireos established markets.'
• He added that the company experienced continued growth in Maryland, stable performance in Minnesota, medical sales declines in New York, and the commencement of New York adult use sales from their indoor facility.
• Mazarakis stated, 'We remain focused on closing our pending merger transactions, expected to begin during the second quarter.'

Industry Context

Vireo's performance reflects the mixed landscape of the cannabis industry, with growth in some markets offset by declines in others. The focus on mergers and acquisitions is a common strategy for companies looking to expand their market presence and improve profitability in a competitive environment.

Comparison to Industry Standards

• Comparing Vireo's adjusted EBITDA margin of 26.8% to other cannabis companies such as Curaleaf (CURLF) and Green Thumb Industries (GTBIF), which have historically reported adjusted EBITDA margins in the range of 25-30%, suggests that Vireo is performing competitively in terms of profitability.
• However, the decrease in operating income margin compared to the previous year indicates potential challenges in managing operating expenses or increased competition affecting pricing.
• The company's revenue growth of 1.9% is relatively modest compared to some of the larger multi-state operators (MSOs) that have experienced double-digit growth rates, but it is in line with expectations for Vireo's established markets.

Legal Proceedings

• The company faces risk of failure in the lawsuit with Verano and the cost of that litigation.

Stakeholder Impact

• Shareholders can expect potential benefits from the pending merger transactions, which are expected to strengthen the company's profitability profile.
• Employees may experience changes as a result of the mergers, but the company's commitment to empowering local market leaders suggests a focus on maintaining strong teams.
• Customers should see continued service and product availability, with potential improvements from the combined entity.
• The company's focus on strategic capital allocation benefits shareholders and ensures long-term sustainability.

Next Steps

• The company expects to close its pending merger transactions during the second quarter of 2025.
• Management will provide additional updates on its combined platform once the merger transactions have closed.
• Additional information relating to the Company’s first quarter 2025 results will be available on EDGAR and SEDAR later today.

Key Dates

Keywords

Vireo Growth, Cannabis, Financial Results, Merger, EBITDA, Revenue, Q1 2025, Marijuana